Wikipedia -WSS

Wikipedia

author：fashion 2025-08-26 10:52:27 - browse：28

The headquarter of Biotechnology company Ionis Pharmaceuticals, consists of glass windows, pale yellow exteriors and plants outside the building — biotech coverage from STAT — courtesy Ionis Pharmaceuticals

Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its experimental therapy for hereditary angioedema benefitted patients — including those taking drugs currently on the market.

In one of the Phase 3 trials, dubbed OASIS, patients with hereditary angioedema, a rare disease characterized by severe bouts of swelling, were given injections of donidalorsen either monthly or every two months. Those in the former group had an 81% lower monthly rate of swelling attacks after 25 weeks than patients given a placebo, while the reduction compared to placebo was 55% for those treated every two months.

The other study, OASISplus, found that donidalorsen’s benefits deepened and converged after up to an additional year of treatment, with swelling attack rates dropping by 92% to 93% regardless of how often patients were dosed. Notably, this study also tracked patients who switched over to donidalorsen from existing therapies meant to prevent swelling attacks, including drugs sold by Takeda and BioCryst Pharmaceuticals. Patients who switched to the Ionis drug saw their swelling attack rates drop by 62% compared to previous treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Alkermes shareholders re

knowledge

hotspot

WSS

Biotech venture capitalists face new demands from investors

How digital therapeutics firms are pivoting after Pear's bankruptcy

Medicare details structure of new drug price negotiation program

Francis Collins on trust in science and how Covid communications failed

Why doctors need education on FDA device approval process

Humana cuts profit projections as Medicare Advantage costs soar

focus

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Affirmative action in medical school literally saved lives

Affirmative action in medical school literally saved lives

Duchenne breakthrough therapy leaves behind pioneering families

How to save PrEP access — and even expand it

Duchenne breakthrough therapy leaves behind pioneering families

Medical records are filled with copy

BioMarin wins approval for gene therapy to treat hemophilia A

Medical records are filled with copy

Heart attack and stroke risk calculators need revising

Cancer drug shortages should be causing more outrage

explore

Copay coupons to count toward deductibles, after Biden court move

Activists slam private health insurers over coverage restrictions

Elizabeth Holmes banned from government health programs

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Copay coupons to count toward deductibles, after Biden court move

Elizabeth Holmes banned from government health programs

knowledge

knowledge

hotspot

knowledge